Highlights of This Issue 1359

PERSPECTIVE
1361 Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development
Philip M. Tedeschi, Alexei Vazquez, John E. Kerrigan, and Joseph R. Bertino

CELL DEATH AND SURVIVAL
1367 Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells
Ping Fan, Heather E. Cunliffe, Philipp Y. Maximov, Fadke A. Agboke, Russell E. McDaniel, Xiaojuan Zou, Pilar Ramos, Megan L. Russell, and V. Craig Jordan

1377 mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress
Clara Tenkerian, Jothilatha Krishnamoorthy, Zineb Mounir, Urszula Kazimierczak, Arkady Khoutorsky, Kirk A. Staschke, Arnold S. Kristof, Shuo Wang, Maria Hatzoglou, and Antonis E. Koromilas

DNA DAMAGE AND REPAIR
1389 YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors

ONCOGENES AND TUMOR SUPPRESSORS
1398 Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure–Function Analysis
Hagai Ligumsky, Tami Rubinek, Keren Merenbalh-Lamint, Adva Yeheskel, Rotem Sertchouk, Shiri Shahmoon, Sarit Aviel-Ronen, and Idi Wolf

1408 Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway
Gregory R. Kardos, Hannah C. Wastyk, and Gavin P. Robertson

1421 Decreased eIF3e Expression Can Mediate Epithelial-to-Mesenchymal Transition through Activation of the TGFβ Signaling Pathway
Guillaume Desnoyers, Laura D. Frost, Lynn Courteau, Michael L. Wall, and Stephen M. Lewis

SIGNAL TRANSDUCTION
1431 Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer
Neil E. Martin, Travis Gerke, Jennifer A. Sinnott, Edward C. Stack, Owe Andreén, Sven-Olof Andersson, Jan-Erik Johansson, Michelangelo Fiorentino, Stephen Finn, Giuseppe Fedele, Meir Stampfer, Philip W. Kantoff, Lorelei A. Mucci, and Massimo Loda

CORRECTION
1441 Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
ABOUT THE COVER

The cover image shows a comprehensive look at four immunohistochemical markers of PI3K activation in prostate cancer. Martin and colleagues sought to define a combined "score" of activation according to PTEN, pAKT, pS6 and stathmin staining. Here the authors show individual tumors ranked according to this four-marker score as well as how this relates to clinical and pathologic features including Ki67, TUNEL, age at diagnosis, lethal outcome, and Gleason score. Please see the article by Martin and colleagues (beginning on page 1431) for more information.